- Home
- AVNS vs CTNM Comparison
AVNS vs CTNM Comparison
Compare AVNS & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVNS | CTNM |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.7M | 575.3M |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AVNS | CTNM |
|---|---|---|
| Price | $13.88 | $14.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.60 |
| AVG Volume (30 Days) | ★ 545.6K | 176.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.59 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $701,200,000.00 | N/A |
| Revenue This Year | $3.28 | N/A |
| Revenue Next Year | $4.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.95 | N/A |
| 52 Week Low | $9.30 | $3.35 |
| 52 Week High | $15.68 | $16.33 |
Technical Indicators
Market Signals| Indicator | AVNS | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 52.38 |
| Support Level | $10.94 | $13.86 |
| Resistance Level | $15.68 | $16.17 |
| Average True Range (ATR) | 0.57 | 0.91 |
| MACD | -0.21 | -0.22 |
| Stochastic Oscillator | 18.39 | 43.25 |
Price Performance
Historical ComparisonAbout AVNS Avanos Medical Inc.
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.